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Abstract: An HPLC-UV method was developed and validated for the determination of lumefantrine in human plasma. Lumefantrine 
and its internal standard halofantrine were extracted from plasma samples using protein precipitation with acetonitrile (0.2% perchloric 
acid) followed by solid-phase extraction with Hypersep C8 cartridges. Chromatographic separation was performed on a Zorbax SB-CN 
HPLC column (3.0 × 150 mm, 3.5 µm) with water/methanol (0.1% TFA) as the mobile phases in a gradient elution mode. Detection 
was performed using UV/vis detector at λ = 335 nm. The method showed to be linear over a range of 50–10,000 ng/mL with acceptable 
intra- and inter-day precision and accuracy. The mean recoveries were 88.2% for lumefatrine and 84.5% for the I.S. The internal stan-
dard halofantrine is readily available from commercial sources. This method was successfully applied to a pharmacokinetic interaction 
study between a first-line antimalarial combination (artemether—lumefantrine) and antiretroviral therapy.
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Introduction
Malaria is a serious and sometimes fatal protozoan 
disease  caused  by  malaria  parasites  (Plasmodium 
vivax, ovale, falciparum and malariae) and transmitted 
by  the  female  Anopheles  mosquitoes.  Symptoms 
of  malaria  include  fever,  chills,  sweats,  headache, 
nausea,  and  vomiting.  Each  year,  malaria  afflicts 
an estimated 350–500 million people and leads to 
1.5–2.7 million deaths worldwide. Nine percent of all 
deaths in children less than 5 years of age are caused 
by the disease, and this percentage is as high as 20% 
in sub-Saharan Africa.1
Lumefantrine (LF), also named benflumetol and 
chemically  (9z)-2,7-dichloro-9-[(4-chlorophenyl) 
methylene]-a-[(dibutylamino)methyl]-9H-fluorene-4-
methanol, is an aryl alcohol antimalarial first synthe-
sized in the 1970’s by the Academy of Military Medical 
Sciences, Beijing, China and registered in China for 
the treatment of malaria in 1987.2 The compound is 
a yellow powder that is poorly soluble in water, oils, 
and most organic solvents, but soluble in unsaturated 
fatty acids and acidified organic solvents. LF is exten-
sively bound (99%) to plasma proteins, mainly high 
density lipoproteins.3 LF as a drug is commercially 
available only in a fixed-dose combination with arte-
mether (Coartem® or Riamet®).4 This combination is 
well tolerated and highly effective and now becoming 
the most recommended first-line treatment for uncom-
plicated falciparum malaria in African countries.
To  support  pharmacokinetic  interaction  study 
between  artemether/LF  and  an  antiretroviral  treat-
ment for patients co-infected with malaria and HIV, 
here  we  describe  an  HPLC-UV  method  to  deter-
mine LF in human plasma. Previously, Mansor et al 
reported an HPLC-UV method with a narrow cali-
bration range (25–800 ng/mL) and requiring a large 
sample  volume  (1  mL).5  Lindegardh  and  cowork-
ers developed HPLC-UV methods to determine LF 
in  plasma  and  sampling  filter  paper.4,6  However, 
the recovery of LF was relatively low (60%–75%), 
and the internal standards used in these methods are 
not  commercially  available.  Our  method  is  based 
on a previously published method with the follow-
ing modifications6: (1) Protein precipitation utilized 
acetonitrile containing 0.2% perchloric acid in place 
of 1% acetic acid, affording an improved recovery 
(∼90%). (2) Use of the gradient mobile phase water 
(0.1%  TFA)  and  methanol  (0.1%  TFA)  which  are 
salt-free solvents, enabled column wash with a high 
percentage of organic solvent. (3) The internal stan-
dard halofantrine is commercially available.
Experimental
Reagents and materials
Lumefantrine (Figure 1) and halofantrine (the internal 
standard, I.S.) were purchased from A.K. Scientific 
Inc.  (Mountain  View,  CA,  USA).  Acetonitrile 
(MeCN), methanol (MeOH), water (H2O), Perchlo-
ric acid (HClO4), and formic acid (HCO2H) were 
obtained  from  Fisher  Scientific  (Fair  Lawn,  NJ, 
USA).  Trifluoroacetic  acid  (TFA)  was  purchased 
from  Sigma-Aldrich  (St.  Louis,  MO,  USA).  All 
chemicals were of HPLC grade. Water was distilled 
water, if not mentioned specifically. Human plasma 
was  purchased  from  Biological  Specialty  Co. 
(Colmar, PA, USA).
Instrumental and analytical conditions
The HPLC system consisted of Waters 1525 binary 
HPLC  pumps,  Waters  717  plus  autosampler,  and 
Waters 2487 dual λ absorbance detector controlled 
by  Waters  Breeze  software  (Version  3.30  SPA). 
  Separation was achieved on a Zorbax SB-CN HPLC 
column (150 × 3.0 mm, 3.5 µm, Agilent), equipped 
with a pre-column filter, used at room temperature. 
The UV/vis detector was set at 335 nm, and injection 
volume was 50 µL. The mobile phases were water 
with 0.1% TFA (A) and MeOH with 0.1% TFA (B) 
pumped at a flow rate of 0.4 mL/min. The gradient 
program consisted of linear segments with 68% B 
(0–4 min), 68%–75% B (4–18 min), 75%–95% B   
(18–19  min),  95%  (19–22  min),  95%–68%  B   
(22–22.5 min), and 68% B (22.5–31 min).
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Figure 1. Chemical structures of lumefantrine and halofantrine (the I.S.).HpLC-UV method to determine lumefantrine in human plasma
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preparation of standard and quality 
control samples
Primary  stock  solutions  of  LF  and  I.S.  were  each 
  prepared at a concentration of 1 mg/mL in MeCN-
water (1:1) containing 0.5% formic acid. These pri-
mary solutions were diluted with MeCN-water (1:1) 
containing 0.1% formic acid to prepare working stock 
solutions and working solutions. The working solutions 
of LF were spiked to blank plasma to obtain calibration 
  standards of 50, 100, 250, 500, 1000, 2500, 5000, 7500 
and 10000 ng/mL. QC samples were spiked at 120, 900 
and 9000 ng/mL by adding the working solutions into 
blank human plasma. Calibration standards and QC 
samples were prepared from separately weighted stock 
solutions. The stock solutions, standards, QC samples, 
and the I.S. working solution (100 µg/mL) were stored 
at −70 °C between uses.
Sample preparation
To a 0.2 mL aliquot of each standard, QC, and blank 
plasma was added 50 µL I.S. (100 µg/mL halofantrine). 
The  mixture  was  precipitated  with  0.5  mL  MeCN 
containing 0.2% HClO4. After vortexing and centri-
fuging, the sample was poured into a pre-conditioned 
Hypersep C8 solid-phase extraction (SPE) cartridge 
(50 mg/1 cc, Thermo-Fisher) and pipet-mixed with 
0.5 mL pre-loaded water. After pipet-mixing, the sam-
ple was drained into the bed and washed with water 
(1 mL × 3) and subsequently 0.5 mL MeCN-water 
(2:3) containing 0.1% TFA. The cartridge was then 
dried under vacuum (∼8 in Hg) for 10 min followed 
by eluting with 0.5 mL MeOH (0.1% TFA). The eluted 
sample was dried at 40 °C with a stream of N2, recon-
stituted with 200 µL MeOH- water (68:32) containing 
0.1% TFA, and transferred into an autosampler vial.
method validation procedure
The method validation was conducted according to the 
guidelines of NIH funded AIDS Clinical Trials Group 
(ACTG),7 which were developed based on Food and 
Drug Administration (FDA) guidelines. Calibration 
curves were obtained by linear regression of the peak 
area ratio of analyte to internal standard (Y-axis) ver-
sus the nominal analyte concentrations (X-axis) with 
a weighting factor of 1/x. The LLOQ was established 
using five samples independent of standards to deter-
mine accuracy and precision. The signal intensity of   
the  LLOQ  was  5-fold  blank  response.  Intra-day 
precision and accuracy were determined by analy-
sis of five replicates of each QC sample (n = 5) at 
low (120 ng/mL), medium (900 ng/mL), and high 
(9000 ng/mL) concentration levels extracted with a 
set of standards in one batch. The same procedure 
was repeated on five different days with new samples 
to determine inter-day precision and accuracy (total:   
n = 25 per concentration level). Precision was reported 
as relative standard deviation (RSD, %) and accuracy 
as percent deviation from the nominal concentration 
(% deviation). Recovery was assessed by comparing 
the peak area of LF or I.S. from the normally pro-
cessed plasma samples to the peak area of LF or I.S. 
from directly injected water-MeCN (1:1) solution with 
the same concentration of LF or I.S. Specificity of the 
assay was tested with 6 different sources of human 
plasma and potential concomitant drugs. The stability 
of LF in human plasma was evaluated at these condi-
tions: 3 freeze-thaw cycles, storage at −70 °C, room 
temperature storage (22 °C), and at different steps in 
the sample preparation process. Each condition was 
tested with QC samples at low and high concentration 
levels in triplicates. Fresh samples were used as refer-
ence. Stock solutions of LF and I.S. were evaluated   
at −70 °C and room temperature (22 °C).
Application to pharmacokinetic study  
in healthy volunteers
Plasma  samples  from  13  healthy  volunteers  were 
tested with this validated method. The clinical study 
was  conducted  at  the  Clinical  and  Translational 
  Science  Institute  Clinical  Research  Center,  San 
Francisco General Hospital. Each subject received 6 
doses of Coartem (80 mg artemether and 480 mg LF) 
twice daily (study days 1–4), at day 4 blood samples 
were collected before the sixth dose and at 0.5, 1, 2, 
4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, and 264 hr 
post-dose for the analysis of LF. Whole blood samples 
were  drawn  into  EDTA-containing  tubes  and  cen-
trifuged at 2000 g for 10 min. The resulting plasma 
samples were stored at −70 °C before analysis.
Results and Discussion
Internal standard selection
The ideal I.S. should possess similar behavior with 
the  analyte  in  the  process  of  sample  preparation, Huang et al
18  Analytical Chemistry Insights 2010:5
LC separation, and detection, and it should not be 
  potentially  present  in  the  samples. The  I.S.  should 
be eluted near the analyte but not overlap with the 
analyte unless different detection channels are used.8 
Efforts on selecting a close analog of LF as the I.S. 
were limited by commercial availability. Finally halo-
fantrine was selected as the I.S. Halofantrine is readily 
available commercially and detectable at 335 nm. The 
recovery of the IS from sample preparation was simi-
lar with LF, with a retention time approximately 6 min 
less  than  LF.  Sporadically  interfering  peaks  were 
observed, but with a relative intensity less than 5% of 
I.S. signal at the final I.S. concentration. The I.S. con-
centration affects the fitting of calibration curve. Too 
high concentration of I.S. results in large error at lower 
end of the calibration curve. The I.S. concentration 
was selected based on its detection signal equivalent 
to the signal of the analyte at a concentration between 
the lower one-third and the middle of the calibration 
range in terms of magnitude. The I.S. concentration in 
the final injection solution was 25 µg/mL. Based on 
its UV response at 335 nm, 25 µg/mL I.S. was equiva-
lent to ∼700 ng/mL LF, which was close to the middle 
point of the calibration curve.
LC optimization
Phosphate  buffer  is  commonly  used  as  a  mobile 
phase  component  in  HPLC-UV  assay  to  maintain 
constant pH. However, phosphate salts tend to pre-
cipitate in the solvent line with increasing organic 
solvent, resulting in instrument failure. We used 0.1% 
TFA instead of phosphate buffer to maintain an acidic 
condition in order to minimize peak tailing. Initially 
MeCN-water  (55:45)  with  0.1% TFA  was  used  as 
mobile phase. However, an interfering peak partially 
co-eluted with the I.S. (Figure 2). This interference 
was  eliminated  by  switching  MeCN  to  MeOH. A 
drawback to using MeOH as a mobile phase is higher 
system pressure compared to MeCN. During the run, 
the LC system pressure ranged from 2500 to 3500 
psi. A representative chromatogram of LF and the I.S. 
from the final method is showed in Figure 3.
Sample preparation
It has been reported that over 99% LF is bound to plasma 
proteins.3 Lindegardh and coworkers found protein pre-
cipitation prior to SPE increased recovery dramatically 
compared to SPE alone.6 The recovery in the reported 
method was in the range of 60%–75%. The recovery 
from liquid-liquid extraction was reportedly over 90%.9 
Loss of LF may occur at the protein precipitation or 
SPE step. No improvement of recovery was achieved 
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Figure 2. Chromatograms of lumefantrine and the I.S. with meCn-water 
(55:45) containing 0.1% TFA as the mobile phase. dash gray line repre-
sented a sample in mobile phase solvents, solid black line represented 
a sample in plasma. A peak interfering with the I.S. was observed from 
the plasma sample.
Figure 3. Representative chromatogram of lumefantrine and the I.S. with 
MeOH-water containing 0.1% TFA as mobile phase in the final method. 
dash gray line is for blank plasma, solid black line is for an LLoQ sample 
in plasma.
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Table 1. Recovery (RE) of lumefantrine and I.S. in the 
assay.
Concentration 
(ng/mL)
Peak area (X10e4), n = 3 RE, %
Clean sample  
(in MeCN-water)
Preextrac- 
tion spiked
Low (120) 2.55 ± 0.04 2.36 ± 0.03 92.5
High (9000) 192.3 ± 2.2 161.3 ± 0.9 83.9
I.S. (25,000) 16.36 ± 0.29 13.83 ± 0.07 84.5HpLC-UV method to determine lumefantrine in human plasma
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with larger volumes of the elution solvent. Therefore, 
LF was expected to be lost during protein precipitation. 
Precipitation of plasma samples with 1% acetic acid in 
MeCN yielded large particles of precipitate. This may 
cause inefficient release of LF from the plasma proteins. 
Interestingly, addition of a stronger acid (0.2% perchlo-
ric acid) in MeCN generated fine particles of the precipi-
tate, which improved the recovery significantly (up to   
90%) (Table 1). In addition, a 10-min drying step was 
added prior to elution of LF from the SPE column as 
residual water could compromise the elution power of 
methanol.
method validation
Linearity: A calibration curve was calculated and fit-
ted by 1/x weighted regression of the peak-area ratios 
of LF to I.S. versus the concentrations of LF over the 
range of 50–10,000 ng/mL. A weighting factor of 1/x 
is necessary because of the wide concentration range 
of the calibration curve. The mean back-calculated 
  values of standards for 5 run days were all within the 
acceptable range (20% for LLOQ,  15% for other 
  standards) (Table 2).
Precision and accuracy: The intra-day and inter-
day precision (RSD) was all within 15% over the 
calibration range (Table 3). The intra- and inter-day 
accuracy (% dev) also met the guidelines that required 
20% for LLOQ and 15% for QC samples.7
Specificity:  We  tested  six  different  sources  of 
human plasma and 12 potential concomitant drugs: 
nevirapine, lopinavir, ritonavir, zidovudine, lamivu-
dine, efavirenz, chloroquine, sulfamethoxazole, trim-
ethoprim, artemether, dihydroartemisinin, tenofovir. 
No significant interfering peaks were observed during 
the retention times of LF and I.S. at the wavelength 
of detection (λ = 335 nm), indicating high specificity 
and selectivity of the method (see supplemental data 
Figure S1 and S2).
Stability: LF was stable in plasma at the tested 
conditions, and LF stock solution was stable for at 
least 9 months in −70 °C (Table 4). The processed 
sample in the reconstitution solvent was stable for at 
least 3 days. However, the processed sample in glass 
tubes without reconstitution solvent was only stable 
for 1 day. If the extracted sample was reconstituted 
after 2 days, recovery dropped to approximately 60%. 
The lower recovery rate was most likely a result of 
acid-catalyzed LF degradation due to residual acid 
(HClO4 or TFA) in the sample. It is also possible that 
the LF-acid salt is unstable.
Application to pharmacokinetic study  
in healthy volunteers
The validated method was used to study the pharmacoki-
netic interaction of LF and an antiretroviral in 13 healthy 
volunteers. After 6 doses of Coartem® (480 mg LF 
twice daily), the plasma concentration—time profile 
Table  2.  Inter-day  average  back-calculated  standard 
concentrations (n = 5).
Theoretic 
Conc 
ng/mL
Mean 
ng/mL
SD Precision 
(RSD, %)
Accuracy 
(% dev)
50 53.6 4.3 8.1 7.2
100 104 4.3 4.1 4.4
250 252 16.2 6.5 0.6
500 511 14.8 2.9 2.1
1000 1020 15.7 1.5 2.0
2500 2504 44 1.8 0.2
5000 5013 82.8 1.7 0.3
7500 7629 105 1.4 1.7
10000 10146 105 1.0 1.5
Slope 0.0013 0
Y-intercept −0.0018 0.0064
R 0.9998 0.0002 0.02
Table 3. Intra-day and inter-day precision (% RSd) and accuracy (% dev) for analysis of lumefantrine in human plasma.
Nominal, ng/mL Intra-day Inter-day
50 120 900 9000 20 120 900 9000
mean, ng/mL 48.9–57.5 123–131 890–957 9082–9555 54.1 126 921 9371
Sd 0.83–2.55 2.30–8.37 10.6–32.6 221–449 3.4 5.3 36 343
RSd, % 1.4–5.2 1.8–6.7 1.1–3.7 2.3–4.9 6.3 4.2 3.9 3.7
% dev −2.2–15 2.3–9.3 −1.1–6.4 0.9–6.2 8.2 5.1 2.3 4.1
n 5 5 5 5 25 25 25 25Huang et al
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Table  4.  Stability  of  lumefantrine  plasma  samples  and 
stocks.
Storage  
conditions
LF level  
(ng/mL)
% Remaining % RSD
3 freeze/thaw  
cycles
Low (120)
High (9000)
99.5
102.9
3.0
1.1
−70 °C for 
9 months
Low (120)
High (9000)
99.4
102.5
3.8
5.4
benchtop 
6 days
Low (120)
High (9000)
100.6
98.9
2.6
1.8
dry residue  
18 hr
Low (120)
High (9000)
104.8
93.9
7.2
6.0
dry residue 
48 hr
Low (120)
High (9000)
57.4
65.7
8.1
17
in LC solvent  
48 hr
Low (120)
High (9000)
92.7
95.3
9.3
4.3
−70 °C for 
9 months
LF Stock  
solution
102 1.5
22 °C, 3 days LF Stock  
solution
100 2.8
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Figure 4. Plasma concentration—time profile of lumefantrine.
over the period of 0–264 hr is shown in Figure 4. 
The precision and deviation for quality controls dur-
ing analysis of LF samples is showed in Table 5. The 
method proved to be robust and reliable. The findings 
of this pharmacokinetic drug interaction study will be 
published separately.
Conclusions
An HPLC-UV method for determination of LF in 
human plasma was developed based on a previously 
published method.6 Fine tuning of the sample prepa-
ration method improved the recovery of LF signifi-
cantly. Gradient elution followed by a wash phase 
with a high percentage of organic solvent minimized 
interference from carry-over impurities. TFA (0.1%), 
instead of phosphate salt, added to the mobile phase 
minimized peak tailing. The internal standard halo-
fantrine used is readily available from commercial 
sources.  This  method  was  validated  based  on 
the  ACTG  guidelines,7  which  are  based  on  FDA 
guidelines.
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Table 5. method performance during clinical sample analysis.
QCs (ng/mL) Low (120) 
n = 22
Medium (900) 
n = 22
High (9000) 
n = 23
Extra-high* (24000) 
n = 10
precision (% CV) 8.1  4.5  5.8 7.5
Accuracy (% dev) 0.81  −0.03  4.3 −1.6
*Extra-high QCs were diluted by 3-fold.
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Figure S2. Chromatograms of potential concomitant drugs in the method. No significant peaks observed during the retention times for LF and I.S.
Figure S1. Chromatograms of different sources of human plasma. Lumefantrine at LLoQ level and the I.S. were included as reference.
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Table S1. matrix effects from different sources of plasma (EdTA as the antocoagulant). plasma samples spiked with 
lumefantrine at 900 ng/mL.
Plasma 
(lot #)
Replicate Anticoa- 
gulant
Conc. 
(LF) ng/mL
Theoretical conc 
(units) ng/mL
Mean 
ng/mL
SD % CV % Dev
1 (23-08172) 1 EdTA 855 900 845 22.1 2.6% −6.1
2 EdTA 861 900
3 EdTA 820 900
2 (23-08176) 1 EdTA 853 900 895 37.6 4.2% −0.5
2 EdTA 908 900
3 EdTA 925 900
3 (23-08180) 1 EdTA 864 900 903 34.1 3.8% 0.3
2 EdTA 918 900
3 EdTA 927 900
4 (55-20429) 1 EdTA 950 900 947 17.2 1.8% 5.2
2 EdTA 962 900
3 EdTA 928 900
5 (23-06316) 1 EdTA 920 900 929 8.1 0.9% 3.2
2 EdTA 930 900
3 EdTA 936 900
6 (22-97035) 1 EdTA 899 900 939 36.5 3.9% 4.4
2 EdTA 949 900
3 EdTA 970 900
Table  S2.  partial  volumes  precision  and  accuracy  for 
lumefantrine.
Nominal concentration: 30,000 ng/mL
Dilution
Sample # 4X 8X 12X
  1 7126 3865 2399
  2 7755 4134 2368
  3 7663 4177 2290
Theoretical Conc. 7500 3750 2500
mean 7515 4059 2352
Sd 340 169 56
CV % 4.5 4.2 2.4
% dev 0.2 8.2 −5.9
n 3 3 3